Last reviewed · How we verify

Carvedilol+Empagliflozin — Competitive Intelligence Brief

Carvedilol+Empagliflozin (Carvedilol+Empagliflozin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker + SGLT2 inhibitor combination. Area: Cardiovascular, Diabetes.

phase 3 Beta-blocker + SGLT2 inhibitor combination Beta-adrenergic receptors; SGLT2 (sodium-glucose cotransporter 2) Cardiovascular, Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Carvedilol+Empagliflozin (Carvedilol+Empagliflozin) — Asan Medical Center. Carvedilol+Empagliflozin combines a non-selective beta-blocker with an SGLT2 inhibitor to reduce heart workload and improve cardiac efficiency while promoting glucose excretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Carvedilol+Empagliflozin TARGET Carvedilol+Empagliflozin Asan Medical Center phase 3 Beta-blocker + SGLT2 inhibitor combination Beta-adrenergic receptors; SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker + SGLT2 inhibitor combination class)

  1. Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carvedilol+Empagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/carvedilol-empagliflozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: